ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1320

Analysis of Risk Factors for Thrombosis in Pediatric Patients with Systemic Lupus Erythematosus

Kyla D. Driest1, Mollie S. Sturm2, Sarah H. O'Brien3, Charles H. Spencer4 and Stacy P. Ardoin5, 1Rheumatology, OSU Pediatrics, Nationwide Children's Hospital, Columbus, OH, 2Nationwide Children's Hospital, Columbus, OH, 3Hematology, Nationwide Children's Hospital, Columbus, OH, 4Rheumatology, Nationwide Childrens Hospital, Columbus, OH, 5Pediatric & Adult Rheumatology, Ohio State University College of Medicine, Columbus, OH

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Avascular necrosis, risk, Systemic lupus erythematosus (SLE), thrombosis and vasculitis

  • Tweet
  • Email
  • Print
Session Information

Title: Pediatric Rheumatology - Clinical and Therapeutic Aspects: Pediatric Lupus, Scleroderma and Myositis (ACR)

Session Type: Abstract Submissions (ACR)

Background/Purpose: Patients with systemic lupus erythematosus (SLE) have a higher thrombotic risk compared to the general population, and arterial and venous thromboses impart substantial morbidity and mortality. Few studies have focused on thrombotic risk within the pediatric SLE (pSLE) population.  We sought to better characterize the risk factors for thrombosis in patients with pSLE utilizing the Childhood Arthritis & Rheumatology Research Alliance (CARRA) registry.

Methods: The CARRA registry contains 979 patients with pSLE. Pediatric SLE patients with a history of thrombosis were compared to those with no history of thrombosis. A history for thrombosis was defined as any patient within the SLE registry who had a history of arterial or venous thrombotic event as reported by the treating pediatric rheumatologist. For continuous variables, the Wilcoxon Mann-Whitney test was used to compare groups. In the case of categorical variables, univariate logistical regression was used to calculate odds ratios (OR). Patients with missing outcome data were excluded from analysis. Statistical Analysis System software 9.3 (SAS Institute Inc., Cary, NC, USA) was used to perform statistical analysis.

Results: Of the 979 patients in the registry, 974 had data recorded for thrombosis and were included in the analysis. The majority of these patients were female (82.4%), non-Hispanic (72.8%) and white (44.7%). Of the 974 patients, 24 (2.5%) had history of arterial thrombosis and 35 (3.6%) of venous thrombosis. Odds ratios for thrombosis were calculated for gender, ethnicity, BMI, race, Raynaud’s phenomenon, vasculitis, avascular necrosis (AVN), renal disease, positive antiphospholipid antibody (APLA), thrombocytopenia, and hydroxychloroquine use. Utilizing a p value of < 0.05 as significant, the odds ratios of having a thrombotic event were significantly higher in patients with vasculitis [3.11, 95% CI: (1.60, 6.01)], history of AVN [3.08, 95% CI: (1.24, 7.67)], or APLA [3.03, 95% CI: (1.45, 6.36)]. Odds ratios for other variables were not statistically significant. 

Conclusion:  Our study of 974 patients with pSLE including 59 with a history of thrombotic event suggests that pSLE patients with a history of vasculitis, positive APLA, and AVN are at a greater risk for thrombotic events than those without. Odds ratios for gender, race, ethnicity, hydroxychloroquine use, renal disease, history of Raynaud’s phenomenon, and thrombocytopenia were not found to be statistically significant within this subset of patients.


Disclosure:

K. D. Driest,
None;

M. S. Sturm,
None;

S. H. O’Brien,
None;

C. H. Spencer,
None;

S. P. Ardoin,
None.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/analysis-of-risk-factors-for-thrombosis-in-pediatric-patients-with-systemic-lupus-erythematosus/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology